Loading…
CytoMed Therapeutics Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in GDTC.
▼ -71.5% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $1.34 | $3.40 | $4.90 | |
| P/S | — | 48.7x | 564.5x | — |
| P/B | 4.4x | 2.4x | 4.4x | 5.0x |
| EPS | — | — | -$0.39 | |
| Profit margin | — | -1227.07% | -3621.10% | — |
| ROE | -36.75% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LNAILunai Bioworks Inc. | $2.37 | — | — | — | -325.46% | $10.75M |
| AZTRAzitra, Inc. | $0.18 | 8.8x | 1.5x | — | -256.67% | $10.72M |
| MTVAMetaVia Inc. | $1.70 | — | 1.6x | — | -175.68% | $11.2M |
| VTGNVistagen Therapeutics, Inc. | $0.25 |
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Company description provided by Yahoo Finance.
| -60.82% |
| -28.07% |
| -36.75% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.5x |
| — |
| -166.46% |
| $11.22M |
| APREAprea Therapeutics, Inc. | $0.84 | — | 0.3x | — | -46.15% | $10.56M |
| TOVXTheriva Biologics, Inc. | $0.25 | 0.2x | 0.9x | — | -101.87% | $11.25M |